Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster.

Disclaimer: This article has been developed and funded by Daiichi Sankyo ... in breast and lung cancer, two of the most common cancers and biggest killers in our society. Precision medicines ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan ... in the press release. According to the American Cancer Society, breast cancer is the most common cancer in ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer. The FDA has approved ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

The trial showed an ORR of 62.6% for Enhertu compared to 34.4% for chemotherapy in HER2-low and HER2-ultralow metastatic breast cancer ... milestone payment to Daiichi Sankyo.

About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that ... for people with cancer, cardiovascular and other ...

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of ...